Esophageal candidiasis

Summary

Esophageal candidiasis (MONDO:0001648) is a disease and 2 clinical trials. Top therapeutic interventions include micafungin. A subtype of fungal esophagitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	esophageal candidiasis
Mondo ID	MONDO:0001648
DOID	DOID:13146
ICD-10-CM	B37.81
NCIT	C27027
SNOMED CT	20639004
UMLS	C0239295
MedGen	66784
Is cancer (heuristic)	no

Also known as: Candida esophagitis · candidal esophagitis · candidiasis of the esophagus · candidiasis of the oesophagus

Disease family

This is a subtype of fungal esophagitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › upper digestive tract disorder › esophageal disorder › esophagitis › fungal esophagitis › esophageal candidiasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00607763	PHASE1	COMPLETED	Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
NCT00608335	PHASE1	COMPLETED	Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MICAFUNGIN	4	2